Sign In
Buy ARVN
$7.70
-0.300 (-3.75%)
At Close: Jun 03, 2026
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
04:30pm, Thursday, 01'st Feb 2024
NEW HAVEN, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
What Makes Arvinas, Inc. (ARVN) a New Strong Buy Stock
01:01pm, Wednesday, 17'th Jan 2024
Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year?
11:17am, Monday, 01'st Jan 2024
Here is how Arvinas, Inc. (ARVN) and ImmunoGen (IMGN) have performed compared to their sector so far this year.
Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade
11:16am, Monday, 25'th Dec 2023
The consensus price target hints at a 42.1% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings est
Arvinas: Positive Breast Cancer Data Leads To Other Developments
04:20pm, Friday, 15'th Dec 2023
Positive interim data achieved by Arvinas, Inc. from phase 1b study using vepdegestrant for the treatment of patients with ER+/HER2- advanced or metastatic breast cancer patients respectively. Two ong
Has Arvinas (ARVN) Outpaced Other Medical Stocks This Year?
11:19am, Friday, 15'th Dec 2023
Here is how Arvinas, Inc. (ARVN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
NEW HAVEN, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
Does Arvinas, Inc. (ARVN) Have the Potential to Rally 145.52% as Wall Street Analysts Expect?
11:18am, Friday, 01'st Dec 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 145.5% in Arvinas, Inc. (ARVN). While the effectiveness of this highly sought-after metric is questionable, the
Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity
02:56am, Friday, 24'th Nov 2023
Arvinas is a leading company in developing protein degraders, with a depressed share price, drugs in advanced study phases, and ample cash reserves. Arvinas is focused on oncology, particularly breast
Arvinas, Inc. (ARVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
11:18am, Monday, 13'th Nov 2023
Arvinas, Inc. (ARVN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among
Strength Seen in Arvinas, Inc. (ARVN): Can Its 6.3% Jump Turn into More Strength?
09:01am, Tuesday, 31'st Oct 2023
Arvinas, Inc. (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ter
Arvinas' Potential In Treating ER+, HER2- Breast Cancer
01:50am, Monday, 04'th Sep 2023
Arvinas focuses on protein degradation therapies, with current projects targeting breast and prostate cancers. Financially, ARVU holds robust liquidity, minimal debt, and a cash runway till 2026; comb
Arvinas to Participate in Upcoming Investor Conferences
07:00am, Friday, 01'st Sep 2023
NEW HAVEN, Conn., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
10:40am, Tuesday, 08'th Aug 2023
Arvinas, Inc. (ARVN) came out with a quarterly loss of $1.25 per share versus the Zacks Consensus Estimate of a loss of $1.67. This compares to loss of $1.32 per share a year ago.
Arvinas, Inc. (ARVN) Moves 17.5% Higher: Will This Strength Last?
06:01am, Tuesday, 13'th Jun 2023
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down t
